Skip to main content
. Author manuscript; available in PMC: 2011 Jan 22.
Published in final edited form as: Vaccine. 2009 Nov 21;28(4):907. doi: 10.1016/j.vaccine.2009.11.002

Table 1.

Characteristics and prior H5 immunization history of the study population1

Gender No. Average Age
(Range)		 Previous recombinant H5/HK/156/97 vaccination and doses
Years 25µg + 25µg 45µg + 45µg 90µg + 90µg 90µg + 10µg
Male 10 41.7
(34–50)		 4 2 3 1
Female 18 42.3
(33–51)		 4 4 5 5
1

Subjects who had participated in an earlier clinical study of experimental vaccination with recombinant HA H5/HK/156/97 and conducted in 1998 [12], were re-enrolled for the present study. In the earlier study, subjects received two doses of rH5 HA in the amounts indicated. The numbers of subjects in each dose category, age, and gender distributions are indicated.